Program Description: 

ISTH Academy Webinar: Cancer Detection in VTE Patients

Marc Carrier "What is the role of cancer screening for patients with VTE?"

Unprovoked venous thromboembolism can be the first manifestation of an undiagnosed cancer. Dr. Carrier will review the incidence of occult cancer detection in this patient population. He will also discuss the optimal management plan and review the evidence supporting the different occult cancer screening strategies.

 

Aurélien Delluc "Management of incidentally-found VTE in cancer patients"

Incidentally discovered pulmonary embolism is more and more frequent. Dr. Delluc will review epidemiological data in this patient population and he will discuss the optimal management plan, especially in cancer patients.  

 

Moderator: Pedro Las Casas

 
 
 
 
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The Medical College of Wisconsin and International Society on Thrombosis and Haemostasis. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
 
Designation of Credit Statement:
The Medical College of Wisconsin designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
More information and online registration:  http://academy.isth.org/ 
 

 

Supported by an unrestricted educational grant from Instrumentation Laboratory

Target audience: 

Clinicians managing patients with unprovoked venous thromboembolism

Learning objectives: 

At the end of this Webinar, the participants will be able to:

  • Review the incidence of occult cancer detection in patients with venous thromboembolism (VTE)
  • Discuss the pros and cons of occult cancer screening in patients with unprovoked VTE
  • Review the literature regarding the efficacy of limited and extensive occult malignancy screening strategies
  • Review the incidence and risk factors of incidentally discovered pulmonary embolism.
  • Discuss the pros and cons of incidentally discovered pulmonary embolism treatment.
  • Review the literature regarding management of incidentally discovered pulmonary embolism. 
Faculty & credentials: 
Planning Committee:
Geoffrey Barnes, MD
Meera Chitlur, MD
Caterina Casari, MD

 

Speakers:

Marc Carrier

Dr. Marc Carrier, M.D., FRCP(C), MSc. is an Associate Professor in the Faculty of Medicine, Departments of Medicine and Epidemiology at the University of Ottawa and a Scientist in the Clinical Epidemiology Program of the Ottawa Hospital Research Institute. Dr. Carrier is holding a Tier 2 Research Chair in Venous Thromboembolism and Cancer from the University of Ottawa and New Investigator Award from the Heart and Stroke Foundation of Canada.

Aurélien Delluc

Dr. Aurélien Delluc, M.D, Ph.D., is a Full Professor of internal medicine at the Western Brittany University, France, a physician in the Department of Internal Medicine and Chest Diseases at Brest University Hospital and a Senior Scientist in the “Groupe d’étude de la thrombose de Bretagne occidentale” Western Brittany Study Group on Thrombosis, EA3878, Ministère de l’Enseignement Supérieur et de la Recherche, France. He was born and trained in France.

His primary research interest is the evaluation of venous thromboembolism risk (VTE) including the overall epidemiology of VTE, links between atherothrombosis and VTE, cancer-associated thrombosis, and VTE risk associated with hospitalization. He is a member of the International Society on Thrombosis and Haemostasis, and a regular reviewer for thrombosis journals. 

Pedro Las Casas

Pedro Las Casas is a medical doctor and Hematology and Hemotherapy fellow at Universidade Federal de Minas Gerais, in Belo Horizonte, Brazil. He has created a network in Latin America among early career professionals to improve the exchange of knowledge in several ways. His areas of research interest include thromboprophylaxis in oncology patients and the incidence of venous thromboembolism, and the role of immune tolerance induction in hemophilia patients. He has been a member of the ISTH Early Career Task Force since the ISTH Congress in Toronto, 2015, and is proud to be part of the Task Force. He hopes to contribute by reaching and involving many other early career professionals in the field of thrombosis and hemostasis, particularly in Latin America, with the ISTH and its activities.

 

All persons in control of content have NO relevant financial relationships to disclose with the exception of the following persons:  

 

Name

Company

Role

Geoffrey Barnes, MDBMS/Pfizer, Blue Cross Blue Shield of MI, AralezResearch Grant, Consulting
Marc Carrier, MD, MSc, FRCPCPfizer, Sanofi, LEO Pharma, Boehringer Ingelheim, Bayer, Bristol-Myers Squibb, OctapharmaAdvisory Board, Speaker, Principal Investigator
Meera ChitlurNovo Nordisk, Genetech, ShireAdvisory Board, Speaker

 
In accordance with the ACCME®  Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved

 

 

 

 

Contact

Name: 
Lacey Schmeidler, MA
Phone number: 
+1 (919) 929-3807
Email: 
[email protected]
Session date: 
05/24/2017 - 9:00am to 10:00am CDT
Location: 
ISTH Webinar Library Once a Month
Carrboro, NC 27510
United States
See map: Google Maps
Add to calendar: 
  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.
Please login or register to take this course.